Portal de investigação
The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Cruz Martins, N
- Costa, JL
Unidades de investigação
Abstract
Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.
Dados da publicação
- ISSN/ISSNe:
- 1475-2867, 1475-2867
- Tipo:
- Review
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Cancer Cell International BioMed Central Ltd.
Citações Recebidas na Web of Science: 4
Citações Recebidas na Scopus: 8
Documentos
- Não há documentos
Filiações
Keywords
- Lung cancer; Adenocarcinoma; Tumour genotyping; Liquid biopsy; Circulating cell-free tumour DNA; Next Generation Sequencing
Proyectos asociados
Doença do Refluxo Gastro-esofágico e Doença Pulmonar
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (Refluxo Gastro-esofágic) . 2020
A importância do diagnóstico na Fibrose Pulmonar Idiopática
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico (FPI) . 2020
Imunoterapia no cancro do pulmão: PD-L1, biomarcador preditivo?
Investigador Principal: Venceslau José Coelho Pinto Hespanhol
Estudo Clínico Académico . 2020
Citar a publicação
Fernandes M,Cruz N,Machado J,Costa JL,Hespanhol V. The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell Int. 2021. 21(1):675. IF:6,429. (2).
